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Laparoscopy and laparoscopic ultrasound have been validated previously as staging tools for pancreatic cancer. The aim of this study
was to identify if assessment of vascular involvement with abdominal computed tomography (CT) would allow refinement of the
selection criteria for laparoscopy and laparoscopic ultrasound (LUS). The details of patients staged with LUS and abdominal CT were
obtained from the unit’s pancreatic cancer database. A CT grade (O, A-F) of vascular involvement was recorded by a single
radiologist. Of 152 patients, who underwent a LUS, 56 (37%) had unresectable disease. Three of 26 (12%) patients with CT grade O,
27 of 88 (31%) patients with CT grade A to D, 17 of 29 (59%) patients with CT grade E and all nine patients with CT grade F were
found to have unresectable disease. In all, 24% of patients with tumours o3cm were found to have unresectable disease. In those
patients with tumours considered unresectable, local vascular involvement was found in 56% of patients and vascular involvement
with metastatic disease in 17%, while 20% of patients had liver metastases alone and 5% had isolated peritoneal metastases. The
remaining patient was deemed unfit for resection. Selective use of laparoscopic ultrasound is indicated in the staging of periampullary
tumours with CT grades A to D.
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Pancreatic cancer remains an important cause of cancer-related
deaths. The majority of patients are unresectable due to liver
metastases, peritoneal metastases or local invasion of vascular
structures. As the outcome in most patients is poor, accurate
staging allows appropriate treatment selection, which usually
consists of nonsurgical palliation.
Laparoscopy with the addition of laparoscopic ultrasound has
previously been shown to be an effective tool in the staging of
pancreatic cancer (John et al, 1995) being more predictive of
resectability than abdominal computed tomography (John et al,
1999). Palliative surgery does not increase the duration of survival
compared to endoscopic stenting (Taylor et al, 2000), however,
operative bypass offers longer palliation of symptoms. If laparo-
scopic staging identifies unresectable disease, this information can
be used to decide the best palliative technique for an individual
patient. With the combined use of CT scanning and LUS,
unresectable disease is found in 35–54% of patients (John et al,
1995; Minnard et al, 1998; Nieveen van Dijkum et al, 2003).
Some authors advocate helical abdominal CT scanning as the
best modality to identify local vascular invasion and metastatic
disease and do not perform laparoscopy or laparoscopic ultra-
sound in the assessment of patients with pancreatic carcinoma
(Pisters et al, 2001). Loyer et al (1996) have described a grading
system of vascular involvement based on a dynamic series of
1.5mm thickness scans in patients with pancreatic adeno-
carcinoma (Table 1). Along with other groups, they have reported
a decreasing rate of resectability with increasing grades of vascular
involvement (Loyer et al, 1996; Phoa et al, 1999; Saldinger et al,
2000).
The aim of this study was to identify if assessment of vascular
involvement with abdominal CT scanning would allow refinement
of the selection criteria for laparoscopic ultrasound in patients
presenting with obstructive jaundice from presumed tumours
arising from the ampulla or head of the pancreas.
METHODS
All patients referred to our specialist unit with pancreatic tumours
were entered onto a pancreatic cancer database. Patients with
tumours of the pancreatic head (including uncinate process) or
ampulla who had undergone LUS for staging of their intra-
abdominal disease were selected for analysis. For inclusion in the
study a pancreatic CT scan was required to be available for
radiological review. Patients with metastatic disease or peritoneal
disease present on CT scanning were excluded from analysis. The
selection of all patients with presumed tumours reflects the true
nature of patients referred for assessment in our unit where we do
not routinely pursue confirmation of a preoperative pathological
diagnosis. All patients had a clinical presentation and CT scan
appearance consistent with a diagnosis of cancer of the pancreatic
head, uncinate process or ampulla.
CT assessment
The protocol for CT staging of suspected pancreatic tumours
involved triple phase CT scanning with 5mm slices during the
arterial phase. During the study period the same spiral CT with a Revised 10 October 2005; accepted 25 November 2005
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ssingle detector was used for all scans. CT scanning performed prior
to referral was only repeated if deemed unsatisfactory by the
radiologist.
A single specialist hepatobiliary radiologist who was blinded to
the outcome of each patient reviewed the abdominal CT scans.
Each tumour was given a CT grade of vascular involvement based
on that described by Loyer et al (1996). This grading system
examines the relationship between the tumour and the major
vessels (superior mesenteric vein, portal vein, superior mesenteric
artery and hepatic artery). Patients with grade A to D tumours are
considered potentially resectable while those with grade E or F
tumours are invariably not resectable (Loyer et al, 1996). In
addition a grade O was added to this grading system for those
patients with pancreatic and biliary duct dilatation without the
presence of a pancreatic mass.
For analysis, grade A to D tumours where grouped together, as
were grade E and F tumours, while grade O tumours were analysed
as one entity.
Follow-up was continued until death and/or by outpatient
review or General Practitioner contact. Patients were considered to
have had benign disease if there had been resolution or no
progression of CT scan changes after 12 months of follow-up.
Laparoscopy and laparoscopic ultrasound assessment
The technique for laparoscopic ultrasound has been previously
described (John et al, 1999). Laparoscopy was performed under
general anaesthesia and if metastatic disease was identified
laparoscopic ultrasound was not performed routinely. Routine
lymph node examination and biopsy was not performed. Results
from all surgeons within the hepatobiliary unit were included.
Laparoscopy was performed as an independent procedure and not
immediately prior to planned resection.
At laparoscopy an unresectable tumour was determined by the
presence of liver or peritoneal metastases as well as visible
invasion through the transverse mesocolon.
Tumour size was measured at laparoscopic ultrasound, however,
it was not used as an indicator of unresectability. Similarly,
invasion of the duodenum, common bile duct or retroperitoneum
was not considered to indicate unresectability.
Ultrasonographic assessment of invasion of the superior
mesenteric vein, portal vein, superior mesenteric artery or hepatic
artery was performed, but particular attention was made of the
right lateral aspect of the splenoportal junction. Vascular invasion
was indicated if there was (a) obliteration or thrombosis of the
vein; (b) a fixed stenosis of the vessel wall; (c) loss of the
hyperechoic vessel–tumour interface with encroachment of
hypoechoic tumour to the vessel margin; (d) vessel encasement
by tumour encirclement and rigidity; (e) presence of tumour
within the vessel lumen (John et al, 1999) (Figure 1). The accuracy
of this technique has previously been validated from this unit
(John et al, 1995).
Patients in whom definite vascular invasion was not confirmed
were still deemed potentially resectable. In general, planned
resection of the portal vein was not undertaken, however,
involvement of a section of the portal vein at laparotomy was
not seen as a contra-indication to resection. Involvement of the
superior mesenteric vein, hepatic artery or superior mesenteric
artery was considered a contraindication to resection.
RESULTS
Between April 1995 and March 2002, 564 patients with pancreatic
tumours were entered onto the unit cancer database. In all, 154
patients with a CT scan available for radiological grading
underwent LUS, however, the procedure was unsuccessful in two
patients. In the remaining 152 patients there were 83 (55%) males
and 69 (45%) females with a median age of 64 years (range 35–83
years). The eventual pathological diagnosis was pancreatic
adenocarcinoma in 93 (61%), presumed pancreatic (but not
Table 1 Definition of vascular involvement assessed by CT scanning
Grade of
resectability Definition
Grade O Biliary and pancreatic duct dilatation without a mass present (addition)
Grade A Fat plane separates the tumour and/or the normal pancreatic parenchyma from adjacent vessels
Grade B Normal parenchyma separates the hypodense tumour from adjacent vessels
Grade C Hypodense tumour is inseparable from adjacent vessels, and the points of contact form a convexity against the vessels
Grade D Hypodense tumour is inseparable from adjacent vessels, and the points of contact form a concavity against the vessels or partially encircle the vessels
Grade E Hypodense tumour encircles adjacent vessels, and no fat plane is identifiable between the tumour and the vessels
Grade F Tumour occludes the vessels
Based on the classification of vascular involvement described by Loyer et al (1996).
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Figure 1 Laparoscopic ultrasound assessment of vascular invasion. (A)
Resectable tumour free from splenoportal junction. (B) Tumour involve-
ment of splenoportal junction. (C) Tumour involvement of the superior
mesenteric artery (BD – bile duct, PD – pancreatic duct, SP – splenoportal
junction, SMA – superior mesenteric artery).
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sbiopsy proven) in 18 (12%), ampullary cancer in 17 (11%), benign
in eight (5%), cholangiocarcinoma in seven (5%), neuroendocrine
in five (3%) and four other diagnoses (3%).
Of the 152 patients who underwent LUS, 56 patients (37%) were
deemed unresectable. Table 2 reports the number of patients in
each CT grade of vascular involvement and the number with
unresectable disease, while Figure 2 illustrates the reason for
unresectability. In all, 12% of patients with CT grade O, 31% of CT
grade A to D, 59% of CT grade E and all CT grade F patients were
found to have unresectable disease.
A total of 96 patients were deemed potentially resectable at
laparoscopic ultrasound and their management is detailed in
Table 3. Nine patients (9%) received nonsurgical palliation due to
patient choice or the development of an intercurrent illness.
Resection was possible in 62 (71%) of the remaining 87 patients,
with 25 found to be unresectable at laparotomy.
Twelve CT grade E patients were deemed potentially resectable.
Ten of these patients underwent a trial dissection, but only three
patients had a resectable tumour. All three patients (aged 46, 59
and 63 years) had no evidence of comorbid disease and of these,
one had a portal vein resection for a neuroendocrine tumour and is
alive with metastatic disease 5 years post resection. The two
remaining patients had pancreatic adenocarcinoma and one is
alive 19 months after surgery while the other died 16 months post
resection.
Of the pancreatic adenocarcinomas, 53 of 111 patients (48%)
were found to have unresectable disease by LUS, while only two of
17 patients (11%) with ampullary tumours were unresectable at
laparoscopic ultrasound.
The median size of all tumours on CT scanning was 3.0cm
(range 0.0–10.0cm). Five of 31 (16%) patients with tumours
smaller than 2.0cm were thought to be unresectable at LUS while
51 of 121 (42%) patients with tumours 2.0cm or larger were
deemed to have unresectable disease. In those 88 patients with
grade A to D tumours, six patients had tumours smaller than
2.0cm in diameter and only one (17%) patient was considered
unresectable at laparoscopy and LUS. Nine of 37 (24%) patients
with tumours smaller than 3.0cm in diameter were deemed
unresectable. Figure 3 details the size of tumours for patients with
CT grades A to D as well as the proportion resectable by LUS.
DISCUSSION
Carcinoma of the head of the pancreas is the sixth commonest
cause of cancer related deaths in the United Kingdom. Despite
improvements in surgery, chemotherapy and radiotherapy the
outlook remains poor with a 1-year survival of only 10% (Office for
National Statistics, 1999). In our experience with pancreatic
cancer, the median survival in unresectable patients is only 6
months (Engelken et al, 2003), however, this increases to 24
months for resectable tumours (Welsh et al, 2004). Survival to 5
years does not indicate cure since half of these patients will
subsequently die from recurrence of pancreatic cancer (Conlon
et al, 1996).
If metastatic disease or unresectable local vascular invasion is
detected during staging then jaundice can be palliated by
endoscopic or radiological biliary stenting (Speer et al, 1987). In
our own specialist experience, survival is similar following surgical
bypass or biliary stenting for the relief of jaundice (Engelken et al,
2003) and this is comparable with the findings of a meta-analysis
of three randomised control trials (Taylor et al, 2000). For patients
Table 2 Detection of unresectable disease at laparoscopic ultrasound
based on CT grade
CT potentially
resectable
CT
unresectable
Grade O A B C D E F
Number 26 32 6 11 39 29 9
Unresectable at laparoscopic
ultrasound
a
3 8 1 4 14 17 9
Percentage deemed unresectable 12% 25% 17% 36% 36% 59% 100%
aLiver metastases, peritoneal metastases or vascular invasion.
Liver metastases
20/57 (35%)
Peritoneal metastases
5/57 (9%)
Anaesthetic
3/57 (5%)
Local invasion
41/57 (72%)
1 (2%)
2 (4%)
2 (4%)
7 (12%)
11 (19%) 3 (5%)
30 (53%)
Figure 2 Reason unresectable at laparoscopic ultrasound.
Table 3 Outcome of 96 patients considered to be resectable at
laparoscopic ultrasound
Outcome n (%) Reason n
Resection 62 (65%) Pancreaticoduodenectomy 61
Local excision 1
Nonsurgical palliation 9 (9%) 9
Palliative surgery 25 (26%) Missed local invasion 14
Missed liver metastases 6
Missed peritoneal disease 1
Extensive nodal involvement 2
Missed liver met and local invasion 2
Total 96 96
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Figure 3 Tumour size on CT for grades A–D and the proportion
resectable (88 patients).
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swith unresectable disease, the presence of distant metastases or
advanced local disease may alter the palliative options. The
detection of liver or peritoneal metastases, or advanced local
disease during LUS therefore aids in the choice of palliative
therapy for each patient.
Accurate staging of pancreatic cancer allows selection of optimal
treatment strategies. In the absence of metastatic disease on
abdominal CT scan, 37% of patients considered for resection in
our series had unresectable disease at laparoscopic ultrasono-
graphy. The majority of these patients were treated with
nonsurgical palliation and therefore avoided an unnecessary
laparotomy. Cost analysis of the radiological staging of pancreatic
cancer has shown that strategies that employ abdominal CT with
laparoscopy or laparoscopic ultrasound were consistently less
expensive than other strategies, including CT alone (McMahon
et al, 2001) with the lower cost resulting predominantly from
savings made by avoiding an unnecessary laparotomy.
Endoscopic ultrasound had also been reported to be a useful
tool in the staging of pancreatic cancer, being more sensitive in
determining vascular involvement than abdominal CT scanning
(Tierney et al, 2001) or angiography (Ahmed et al, 2001). However,
the limitation of endoscopic ultrasound is that it is operator-
dependant and cannot detect small volume peritoneal disease or
small subcapsular liver metastases that can be visualised during
laparoscopic ultrasound. Although laparoscopic ultrasound is also
a highly operator dependant staging tool, we have previously
verified the laparoscopic findings by confirmation with laparotomy,
laparoscopic biopsy or angiography, to give a sensitivity for
unresectable disease of 92% and specificity of 88% (John et al, 1995).
Proponents of fine slice helical CT scanning report resection
rates of 80% following CT staging (Pisters et al, 2001). However, in
this report portal vein resection was regularly undertaken and
therefore the potential benefit of assessment of vascular invasion
by laparoscopic ultrasonography would have been minimised.
Other authors believe that open surgical palliation has consider-
able advantage over endoscopic palliation (Nieveen van Dijkum
et al, 2003) and therefore regard LUS as conferring little additional
benefit. Since portal vein resection is not performed routinely in
our unit, nonoperative palliation is preferred and laparoscopic
ultrasound remains an important staging tool.
In the report of Loyer and co-workers, there was an increased
likelihood of detection of unresectable disease with increasing CT
grades of vascular involvement (Loyer et al, 1996). All of the 22
patients with grade A and B tumours were resectable with only one
patient requiring venous resection. Eight of the nine (88%)
patients with grade C tumours were resectable with three requiring
venous resection. Eight of 15 patients (53%) with grade D tumours
were resectable with six requiring venous resection. No tumours in
grade E and F were resected with a negative margin. This study
confirms the finding of decreasing likelihood of resection with
increasing grade of vascular involvement. The difference in the
resectability rates in this series compared to those described by
Loyer and co-workers is explained by the addition of a grade O and
the low rate of portal vein resection in this series.
Only three of 26 (12%) patients with grade O tumours were
deemed unresectable at laparoscopic ultrasound and therefore, in
this subgroup of patients, routine laparoscopic ultrasound is not
justified. Previous authors have found all patients with grade F to
be unresectable (Loyer et al, 1996) and this was confirmed in the
present study. Therefore, there is clearly no benefit in undertaking
laparoscopic ultrasound in those patients with vascular occlusion
on CT scan. Tumour size has been suggested as an indicator for
predicting patients with a higher risk of metastatic disease (Pisters
et al, 2001), however, we did not find tumour size to be useful in
selecting patients for laparoscopic ultrasound.
Almost one in three patients with grade A to D tumours avoided
an unnecessary laparotomy following laparoscopic ultrasound.
Most patients with grade E tumours were not resected and
therefore laparoscopic ultrasound should be reserved for the
staging of young fit patients who are keen to undergo surgery
despite the low chance of resection, and in whom nonsurgical
palliation is being considered.
Patients who present with gastric outlet obstruction and CT
imaging demonstrating a potentially resectable tumour should
undergo laparotomy as a hepaticojejunostomy and gastroenter-
ostomy can be performed readily if the tumour is unresectable. If
CT scanning shows unresectable disease, consideration should be
given to performing laparoscopic gastroenterostomy and endo-
scopic biliary stenting.
Of those patients deemed to be resectable at laparoscopic
ultrasound, approximately a quarter were shown consequently to
have unresectable disease. The most likely reason for tumour
unresectability in this series was local vascular involvement. Some
of these patients were found at laparoscopic ultrasound to have
tumour close to the vessels and were given the chance of a trial
dissection. Arterial vascular involvement is a contraindication to
resection, however, some authors have reported satisfactory results
for portal vein resection (Kawada et al, 2002).
Further technological improvements in CT, MRI (Ishiguchi et al,
2001) and positron emission tomography (Mertz et al, 2000), as
well as the use of biochemical markers such as C-reactive protein
(Engelken et al, 2003; Falconer et al, 1995) may further refine the
indications for laparoscopic ultrasound.
The assessment of vascular involvement with abdominal good
quality CT scanning has allowed better definition of the indications
for laparoscopic ultrasound. Laparoscopic ultrasound should
continue to be used for patients with grade A to D tumours and
selected patients with grade E tumours. However, it is not
indicated for those patients with no evident mass lesion (grade
O) or grade F tumours (vascular occlusion).
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